OmniAb, Inc.
OABIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United. Valued at $677.5M, OABI is a small-cap name in its sector. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Market Cap
$677.5M
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
-15.93
EPS (TTM)
$-0.36
EPS (Fwd)
$-0.29
ROE
-17.0%
ROA
-8.3%
Cash
$52.0M
Total Debt
$18.9M
Free CF
-$285,000
52W Change
193.1%
Annual Financials
Cash vs Debt
Where OABI stands vs its 150-day and 200-day moving averages
As of the October 2, 2026 close, OABI finished 93.41% above its 150-day moving average ($2.58) and 107.92% above its 200-day moving average ($2.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OABI overbought or oversold?
At the October 2, 2026 close, OABI's RSI(14) was 75.6, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $52.0M in cash comfortably exceeding the $18.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$285K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -17.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $59.1M (2022) to $18.7M (2025), a 68% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing OABI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.